MYPT2 inhibitors are a class of chemical compounds that specifically target the MYPT2 protein, which is a subunit of protein phosphatase 1 (PP1). This protein complex is involved in various cellular functions, playing a key role in the regulation of phosphorylation states of many proteins. MYPT2 itself is crucial in directing the activity of PP1 to specific substrates, and thus, its inhibition can have significant effects on the phosphorylation balance within the cell. The chemical compounds that act as MYPT2 inhibitors are typically designed to bind to the protein and attenuate its interaction with PP1 or its substrate proteins. The design of such inhibitors is a complex task that involves understanding the intricate details of the protein's structure and its interaction dynamics. Researchers employ a wide array of techniques, including computational modeling and structure-based drug design, to predict the binding affinity and specificity of potential inhibitors.
The chemical synthesis of MYPT2 inhibitors is a sophisticated process that often requires several iterations of optimization to achieve compounds with high specificity and potency. These inhibitors must effectively bind to MYPT2 in a manner that prevents its normal function without affecting other proteins within the PP1 family or other unrelated proteins. The inhibitors may target the catalytic domain of MYPT2, its regulatory regions, or its interface with PP1, with the goal of disrupting the normal regulatory role of MYPT2. Achieving selectivity is particularly challenging given the conserved nature of phosphatase proteins and their interacting domains. The specificity of MYPT2 inhibitors is critical to their effectiveness, and it is often enhanced through the incorporation of unique chemical groups that interact with distinct amino acid residues of the MYPT2 protein. These interactions may involve hydrogen bonding, hydrophobic interactions, and electrostatic forces, which together contribute to the binding affinity and inhibitory potency of the compounds.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of ROCK1 and ROCK2, leading to reduced phosphorylation of MYPT1, which shares similar regulatory pathways with MYPT2. | ||||||
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $32.00 $85.00 $165.00 $248.00 $486.00 $910.00 | 5 | |
A ROCK inhibitor that can decrease the phosphorylation level of myosin-binding subunits, potentially affecting MYPT2 function. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $39.00 $123.00 $230.00 | ||
A highly selective ROCK1 inhibitor that may indirectly alter MYPT2 activity through the RhoA/ROCK signaling cascade. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $102.00 $357.00 | 7 | |
A potent inhibitor of ROCK that could lead to changes in myosin phosphatase activities, including those related to MYPT2. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $278.00 $622.00 | 15 | |
A ROCK inhibitor that may prevent the phosphorylation of substrates involved in the same pathway as MYPT2. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Known to interfere with lysosomal activity and autophagy, which can modulate the RhoA/ROCK pathway and thus MYPT2 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
A selective inhibitor of the N-WASP which acts upstream of RhoA, potentially influencing MYPT2 activity by modulation of the cellular actin cytoskeleton. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
An inhibitor of myosin light chain kinase (MLCK) that could impact the phosphorylation state of myosin light chains and thus indirectly affect MYPT2. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $71.00 $260.00 $485.00 $949.00 | ||
Inhibits myosin II ATPase activity, which could lead to downstream effects on the phosphorylation state of myosin phosphatase target subunits. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
A PKC inhibitor which may alter the phosphorylation state of proteins in the RhoA/ROCK pathway, with potential effects on MYPT2 regulation. | ||||||